GP100与GPNMB分子水平在黑素瘤预后中的意义

Evaluation of GP100 and GPNMB on the prognosis of patients with melanoma

目的:探讨可溶性分子GP100和GPNMB在黑素瘤诊断及预后中的意义。方法:采用ELISA检测分析健康对照组、良性黑素瘤组及黑素瘤组患者血清中GP100与GPNMB的分子水平变化。结果:良性黑素瘤组患者血清中GP100平均含量为(4.83±1.13)ng/mL,是健康对照组的4.1倍(P<0.05);而恶性黑素瘤组为(13.82±2.19)ng/mL,是健康对照组的12倍(P<0.01)。良性黑素瘤组患者血清中GPNMB的平均含量为(2.56±0.84)ng/mL,是健康对照组的2.7倍(P<0.05);而恶性黑素瘤组平均含量为(15.34±2.52)ng/mL,是健康对照组的16.68倍(P<0.01)。GP100与GPNMB的水平与黑素瘤恶性程度呈正相关。当恶性黑素瘤患者GP100的含量≥5.43 ng/mL,平均生存周期为11个月;而<5.34ng/mL,平均生存周期为35个月,两者之间差异有统计学意义(P<0.01),表明可溶性GP100含量与黑素瘤患者预后呈负相关(P<0.05)。GPNMB含量≥2.72 ng/mL时,恶性黑素瘤患者预后平均存活时间约为11.3个月;<2.72 ng/mL时,预后平均生存期为36个月,两者之间差异有统计学意义(P<0.01)。GPNMB与黑素瘤患者预后呈负相关。结论:血清中GP100及GPNMB的含量是影响黑素瘤患者预后的因素之一,有助于黑素瘤患者的预后评估。

Objective：To explore the correlation between the serum levels of GP100 and GPNMB and the prognosis of human melanoma.Methods：The serum levels of GP100 and GPNMB were quantitatively using ELISA in healthy control,melanoma benign or melanoma patients.Resuits：The G P100 concentrations of begin melanoma and melanoma patients were （4.83 ±1.13） ng/mL （4.1 times versus control）and 13.82 ± 2.19 ng/mL （12 times versus control）,respectively.Whereas the levels of GPNMB were （2.56 ± 0.84） ng/mL （2.7 times versus control） and （15.34 ± 2.52） ng/mL （16.68 times versus control）in begin and melanoma patients,separately.In addition,for 97 begin melanoma patients; increased serum levels of GP100 and GPNMB at diagnosis were associated with a poor prognosis.Patients with GP100 concentrations below or above 5.43 ng/mL had obviously different survival times （median ＞ 35 months or ＜11 months,respectively）.Simultaneously,patients with GPNMB levels up or down 2.72 ng/mL still exhibited a poor prognosis （median ＞36months or ＜11.3 months,respectively）.Conclusion：The levels of GP100 and GPNMB play important roles in the pathogenesis of melanoma and exert crucial function in the prognosis of melanoma patients.Therefore,both of these two molecules will be new independent prognostic indicators.